Even if there is a clear market rotation, these top performing ETFs will have an opportunity to secure gains and move on to be potential trophy winners in 2024.
A competitor's clinical trial stumble may be benefiting MoonLake.
Markets headed into a holiday week cheering a lower-than-expected key inflation reading, but investors should expect volatility in a short trading week.
Positive mid-stage results fueled a spike in the biotech's shares this week.
Clinical-stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive clinical trial results.
The heavily bullish sentiment on the company only grew on the second trading day of the week.
The company reported positive phase 2 clinical trial results.
MoonLake Immunotherapeutics (NASDAQ: MLTX) has made significant strides with the successful outcome of their Phase 2 MIRA trial for sonelokimab,
Markets looked poised to start the new week flat.
September S&P 500 futures (ESU23) are down -0.12%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.22% this morning as market participants looked ahead to the release of the Fed’s favorite...